UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2019
Commission File Number: 001-37643
KITOV PHARMA
LTD.
(Translation of registrant’s name into
English)
One Azrieli Center, Round Tower,
132 Menachem Begin Road, Tel Aviv 6701101,
Israel
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov Pharma
Ltd.
(the “Company” or the “Registrant”) is announcing the results of its Special General Meeting of Shareholders
of the Company held on April 29, 2019 (the “Special Meeting” or the “Meeting”).
At the Special Meeting, management presented certain matters, and the shareholders of
the Company voted on a number of different proposals, all of which are described in more detail in the Company’s Proxy Statement
for the Special Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K that the Company furnished
to the Securities and Exchange Commission on March 22, 2019, as such Proxy Statement was supplemented by a Report of Foreign Private
Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on April 8, 2019 (collectively, the “Proxy
Statement”).
The proposals presented at
the Meeting, (i) to approve the transactions for the acquisition of FameWave and the ADS, warrant and option issuances by the Company
to be made in connection with the Company’s transactions for the acquisition of FameWave and the concurrent investment in
the Company by certain investors and shareholders of FameWave in a private placement, as set forth under Proposal 1 in the Proxy
Statement; (ii) to approve an increase in the number of ordinary shares reserved under Kitov Pharma Ltd. 2016 Equity-Based Incentive
Plan to 7,500,000 ordinary shares to qualify for incentive stock options for US Tax purposes, as set forth under Proposal 2 in
the Proxy Statement; and (iii) to approve the grant of equity-based incentive compensation to each director of the Company, as
set forth under Proposal 3 in the Proxy Statement, were each approved by the requisite vote of the Company’s shareholders
present and voting at the Meeting.
Following receipt
of the approval of the Company’s shareholders for the Transaction for the acquisition of FameWave, and the finalization
of a clinical collaboration agreement between FameWave and Bristol Myers Squibb (NYSE:BMY) for their planned Phase 1/2 clinical
trials to evaluate the combination of CM-24, a monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related
cell adhesion molecule 1 (CEACAM1) with nivolumab (Opdivo®), a PD-1 inhibitor which was recently announced, the Transaction
is expected to close during the third quarter of 2019, subject to fulfillment of certain additional closing conditions, as set
forth in the Proxy Statement. If any condition to the closing of the Transaction is not satisfied or waived, the Transaction may
not be completed in full or in part.
The
Stock Purchase Agreement with respect to the Transaction for the acquisition of FameWave, as amended, which was filed as
an annex to the Proxy Statement and as an exhibit to the Company’s Annual Report on Form 20-F for 2018, as
amended, remains in full force and effect as originally executed. The foregoing description of the remaining closing
conditions and the transactions contemplated by the Stock Purchase Agreement does not purport to be complete and is subject
to, and qualified in its entirety by, the full text of the Stock Purchase Agreement, as amended.
This
disclosure concerning the approval of the Company shareholders for the Transaction for the acquisition of FameWave, supplements
the disclosures concerning the Transaction which are contained in each of the Proxy Statement and the Company’s Annual Report
on Form 20-F for 2018, and should be read in conjunction with each of such documents. They are available on the internet site maintained
by the Securities and Exchange Commission at http://www.sec.gov, along with periodic reports and other information the Company
files with, or furnishes to, the Securities and Exchange Commission. To the extent that the information set forth herein differs
from or updates information contained in the Proxy Statement, the information set forth herein shall supersede or supplement the
information in the Proxy Statement. Terms used herein, unless otherwise defined, have the meanings set forth in the Proxy Statement.
Other
than as expressly set forth above, this Form 6-K does not, and does not purport to, amend, update or restate the information in
any other item of the Proxy Statement, or reflect any events that have occurred after the Forms 6-K with the Proxy Statement were
originally filed.
Forward-Looking Statements and
the Company’s Safe Harbor Statement
Certain statements in this
Report on Form 6-K are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking
words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”,
“could”, “might”, “seek”, “target”, “will”, “project”,
“forecast”, “continue” or “anticipate” or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue
reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect
our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,
involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause
our actual results, performance or achievements to be significantly different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Any forward-looking statement in this Report on Form 6-K speaks only as
of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement,
or other information contained herein, whether as a result of new information, future events or otherwise, except as required by
applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available
on the SEC’s website, http://www.sec.gov
.
This Form
6-K is incorporated by reference into each of the Registrant’s Registration Statements
on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117, 333-211477
and 333-215037), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on
May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities
and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on
Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),
and the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019
(Registration file number 333-230584).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
KITOV PHARMA LTD.
|
|
|
April 29, 2019
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024